Company intelligence / Profile preview

ImmunoShield Therapeutics

Phoenix / Tempe area, Arizona, United Statesflinn.org ↗

Ownership: Private
Development stage: Other

Overview

ImmunoShield Therapeutics is developing a dual-platform approach to enable safe and effective allogeneic cell therapies without the need for chronic systemic immunosuppression. Their technologies include macroencapsulation devices that physically shield therapeutic cells from the host immune system and methods to induce antigen-specific immune tolerance. No clinical results have been published as of June 2025.

Therapeutic areas: Other
Modalities: Cell therapies (allogeneic)Macroencapsulation devicesTolerogenic cell approaches
Industry: Biotech

Partnerships

Engaged in partnerships with pharma and biotech leaders to expedite development/delivery, but no named partners disclosed publicly

Beyond the preview

Go deeper on ImmunoShield Therapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ImmunoShield Therapeutics.

Explore the full profile